8-K

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 30, 2005

MEDTOX SCIENTIFIC, INC.
(Exact name of registrant as specified in its charter)

Delaware	1-11394	95-3863205
(State or other jurisdiction	(Commission File Number)	(IRS Employer
of incorporation)		Identification No.)

402 West County Road D, St. Paul, Minnesota	55112
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (651) 636-7466

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

|_| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

|_| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 3.02.    Unregistered Sales of Equity Securities.

On August 30, 2005, MEDTOX Scientific, Inc. issued a total of 185,186 shares of its common stock upon exercise of warrants issued by the Company in August 2000. The Company received $1,250,005.50 in proceeds from the exercise of the warrants, reflecting the $6.75 per share exercise price. There were no sales discounts or commissions paid in connection with the exercise of the warrants. The shares of common stock underlying the warrants were issued in transactions exempt from registration by virtue of Section 4(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Regulation D promulgated thereunder.

Item 8.01.    Other Events

On September 1, 2005, MEDTOX Scientific, Inc. issued a press release announcing that holders of warrants exercisable for an aggregate of 609,220 shares of the Company’s common stock exercised such warrants. The press release has been filed as Exhibit 99.1 to this Form 8-K.

Item 9.01.    Financial Statements and Exhibits.

(c) Exhibits.

        The following exhibit is filed as part of this report:

Exhibit No.	Description
99.1	MEDTOX Scientific, Inc. Press Release, dated September 1, 2005.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	MEDTOX Scientific, Inc.
Date:   September 1, 2005	By:          /s/ Richard J. Braun
	Name:     Richard J. Braun
	Title:       Chief Executive Officer

3

INDEX TO EXHIBITS

Exhibit No.	Description
99.1	MEDTOX Scientific, Inc. Press Release, dated September 1, 2005.

4

EX-99

Exhibit 99.1

MEDTOX Scientific, Inc.
402 West County Road D
St. Paul, MN 55112
Contact: Joseph Jennings (877) 715-7236

FOR IMMEDIATE RELEASE

MEDTOX SCIENTIFIC, INC. ANNOUNCES FINAL CONVERSION OF WARRANTS

ST.  PAUL, September 1, 2005 – MEDTOX Scientific, Inc. (AMEX-TOX), announced today that the holders of warrants exercisable for an aggregate of 609,220 shares of the Company’s common stock exercised such warrants prior to their expiration in the months of July and August 2005. The Company issued 405,514 shares of its common stock in July 2005, and 185,186 shares in August 2005, upon exercise of such warrants. The remaining shares underlying the exercised warrants were issued in December 2004 and January 2005. The Company received $4,112,235 in proceeds from the exercise of such warrants, reflecting the $6.75 per share exercise price. The warrants exercised were issued in August 2000. The Company issued warrants exercisable for a total of 1,120,439 shares of its common stock at that time. Warrants exercisable for an aggregate of 511,219 shares expired in July or August 2005 without being exercised.

MEDTOX Scientific, Inc., headquartered in St. Paul, Minn., is a provider of high quality specialized laboratory testing services and on-site/point-of-collection (POC) devices. The company also supports customers with complete logistics, data and program management services. MEDTOX is a leader in providing esoteric laboratory testing services to hospitals and laboratories nationwide. This includes both central laboratory and bio-analytical testing for pharmaceutical clinical trials. MEDTOX develops and manufactures diagnostic devices for quick and economical on-site/point-of-collection analysis for drugs-of-abuse, therapeutic drugs and biological and agricultural toxins and provides employment drug screening and occupational health testing. For more information see www.medtox.com.